Atara Biotherapeutics Announced The Closing Of The Expanded Global Partnership With Pierre Fabre Laboratories For Tabelecleucel
Portfolio Pulse from Benzinga Newsdesk
Atara Biotherapeutics has completed an expanded global partnership with Pierre Fabre Laboratories for Tabelecleucel (tab-cel). Atara receives $27 million upfront and initial inventory purchase, with the potential to earn up to $640 million plus royalties on net sales. The deal includes up to $100 million in regulatory milestones through BLA approval, reimbursement of tab-cel global development costs, and future inventory purchases.
December 20, 2023 | 9:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Atara Biotherapeutics has finalized an expanded partnership with Pierre Fabre, receiving $27 million upfront and potential for $640 million plus royalties. The deal supports tab-cel development and secures reimbursement of costs and future inventory purchases.
The closing of this partnership is a significant financial event for Atara, providing immediate cash inflow and the potential for substantial future payments. The upfront payment and reimbursement of development costs reduce financial risk and support ongoing operations. The potential for future royalties and milestone payments is likely to be viewed positively by investors, potentially increasing the stock's attractiveness in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100